A Pennsylvania federal judge issued a preliminary injunction blocking Boehringer Ingelheim Pharmaceuticals from conveying in training materials for its sales representatives false or misleading information about rival GlaxoSmithKline LLC's inhalers for patients with chronic obstructive pulmonary disease. Stephen J. Kastenberg, Paul Lantieri III, Matthew I. Vahey and Emilia L. McKee Vassallo represent GSK.

Read the full article here. Subscription may be required.